Wound Management Technologies Announces Cytokine Study Presentation at the Tri-Society Annual Conference 2009 in Lisbon, Portugal

FORT WORTH, Texas, Nov. 3 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM), announced today that a clinical study, "Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures" was presented at the Tri-Society Annual Conference 2009 of the Society for Leukocyte Biology, International Cytokine Society, & International Society for Interferon and Cytokine Research, Cellular and Cytokine Interactions in Health and Disease in Lisbon, Portugal, October 18-21, 2009.

The abstract was presented by authors Gregory B. Pott, K. Scott Beard, and Leland Shapiro, of the Department of Medicine, University of Colorado Denver, Aurora, Colorado and included data of patients with lower extremity diabetic ulcers by Matthew Regulski, Wound Care Center of Ocean County, New Jersey.

The study suggests that activated collagen (CellerateRx) alone was a potent inducer of IL-6 and the neutrophil chemo-attractant, IL-8, which are important for the acute response to injury and bacterial infection. The study showed that treatment of diabetic ulcers with activated collagen (CellerateRx) and standard therapy significantly accelerated wound healing compared to standard therapy alone. As well, activated collagen (CellerateRx) significantly increased spontaneous (unstimulated) levels of IL-8, IL-6, and IL-10. These results suggest that CellerateRx enhances wound healing, and a possible mechanism involves specific modulation of the cytokine response in bacteria-containing wounds.

Briefly, this groundbreaking research suggests:

• Treatment of diabetic ulcers with activated collagen (CellerateRx) and standard therapy significantly accelerated wound healing compared to standard therapy alone
  

• Activated collagen (CellerateRx) significantly increased spontaneous (unstimulated) levels of IL-8, IL-6, and IL-10
  

• A biphasic activated collagen (CellerateRx) effect on TNF(alpha) and IL-1(beta) was shown
  

"This is a very exciting study for us," stated Cathy Bradshaw, President of Wound Care Innovations. "Dr. Shapiro is a leading authority with worldwide recognition and has published extensively on this subject. These results suggest a scientifically rational mode of action which addresses the results clinicians have seen with CellerateRx."

CellerateRx is FDA cleared for use on acute and chronic wounds which include but are not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and 1st and 2nd degree burns.

About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is leveraging its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering. WNDM also believes it is positioned to develop its technology in Cancer Treatment. For more information on the Company please visit www.woundmanagementtechnologies.com or call our shareholder information department at 1817 820 7080.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

    For Further Information:
    Product Information                   Shareholder Relations
    Cathy Bradshaw                        Ronnie Ambrose
    President                             954-357-0614
    954-357-0614